Publications by authors named "E H Laghmani"
Background: Despite improvements in therapy, breast cancer still contributes to high mortality rates. Survival of these patients becomes progressively worse upon diagnosis with cancer-associated thrombosis (CAT). Unfortunately, the mechanism causing CAT has remained unclear.
View Article and Find Full Text PDFArticle Synopsis
- Cancer increases the risk of venous thromboembolism, particularly in glioblastoma cases, highlighting the need for new models to study this issue at a molecular level.
- A novel cancer-on-a-chip model was created to analyze how glioblastoma cells affect blood coagulation by co-culturing glioblastoma spheroids with endothelial cells.
- Results showed that glioblastoma cells significantly heightened blood coagulation, and using anticoagulant drugs like rivaroxaban effectively reduced this coagulation in the model, suggesting its potential for discovering new anticoagulant therapies for glioblastoma and similar cancers.
Novel biomarkers are needed to improve current imperfect risk prediction models for cancer-associated thrombosis (CAT). We recently identified an RNA-sequencing profile that associates with CAT in colorectal cancer (CRC) patients, with REG4, SPINK4, and SERPINA1 as the top-3 upregulated genes at mRNA level. In the current study, we investigated whether protein expression of REG4, SPINK4 and alpha-1 antitrypsin (A1AT, encoded by SERPINA1) in the tumor associated with CAT in an independent cohort of CRC patients.
View Article and Find Full Text PDFArticle Synopsis
- Glioblastoma patients have a high risk of developing venous thromboembolism (VTE), and researchers aim to understand the genetic and signaling factors that contribute to this risk.
- Using RNA sequencing, researchers compared gene expression profiles of glioblastoma patients with VTE to those without and identified 1246 differentially expressed genes, including GLI1, which is linked to the Sonic Hedgehog signaling pathway.
- The findings suggest that the Sonic Hedgehog pathway may play a significant role in the risk of VTE among glioblastoma patients, particularly those with certain tumor subtypes.
Glioblastoma (GBM) patients have one of the highest risks of venous thromboembolism (VTE), which is even further increased upon treatment with chemotherapy. Tissue factor (TF) is the initiator of the extrinsic coagulation pathway and expressed by GBM cells. In this study, we aimed to examine the effect of routinely used chemotherapeutic agents Temozolomide (TMZ) and Lomustine (LOM) on TF procoagulant activity and expression in GBM cells in vitro.
View Article and Find Full Text PDF